This article is more than 5 years old. Information may no longer be current.

VIDEO: Giles discusses cardiovascular safety of tocilizumab

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

WASHINGTON — At the American College of Rheumatology Annual Meeting, Jon T. Giles, MD, MPH, assistant professor of medicine in the Division of Rheumatology at Columbia University, reviewed a study that compared the cardiovascular safety of etanercept to tocilizumab, which was previously found to increase circulating levels of cholesterol.

In this study of patients with active rheumatoid arthritis and with cardiovascular risk factors, researchers found no difference in the occurrence of stroke, heart attack or cardiovascular death between the two drugs, which had an average follow-up of 3.2 years. Giles said these results were reassuring.